Designing cannabis trials for dying patients involves six unique challenges beyond standard clinical research—from navigating cannabis legislation to managing product variability and compassionate access.
Researchers planning cannabis clinical trials, palliative care clinicians involved in research, ethics committees reviewing cannabis protocols, and regulatory bodies overseeing medicinal cannabis.
What the researchers found
This paper is a practical roadmap for researchers, drawn from the investigators' experience running a Phase I/IIb trial of vaporized cannabis for cancer anorexia. Using action research methodology, they documented the challenges they encountered and synthesized them into six key design considerations.
The six considerations: (1) Operating within medicinal cannabis legislation—which varies by jurisdiction and is often changing mid-trial. (2) Bioethical considerations unique to cannabis (stigma, patient expectations, the politics of evidence). (3) Feasibility challenges in palliative populations (recruitment, retention, cognitive capacity to consent). (4) Pharmacological complexity (variable plant composition, limited standardization, drug interactions). (5) Product requirements (quality control, dosing consistency, shelf life). (6) Regulatory hurdles specific to cannabis as an investigational product.
Palliative care adds layers of complexity that don't exist in other cannabis research: patients are seriously ill, may deteriorate rapidly during a trial, have complex medication regimens, and face existential concerns that shape their relationship with any potential treatment. The intersection of cannabis complexity and palliative care complexity creates unique challenges that this paper aims to help future researchers navigate.
Why it matters
The evidence base for cannabis in palliative care can only grow if researchers can actually conduct the trials. Many well-intentioned cannabis studies fail due to regulatory, logistical, or ethical barriers that could have been anticipated. This paper provides a practical blueprint for navigating those barriers, potentially accelerating the pace of palliative cannabis research.
The numbers in context
6 key design considerations identified. Phase I/IIb trial of vaporized cannabis for cancer anorexia. Action research audit trail from investigator meetings.
How the study worked
Action research methodology applied to a Phase I/IIb trial of vaporized medicinal cannabis for anorexia in advanced cancer (ACTRN12616000516482). Notes from trial investigator meetings served as an audit trail. Data integrated and synthesized to identify key design considerations.
Who was studied
Focus on people receiving palliative care, particularly those with advanced cancer.
What this study cannot tell us
Based on a single trial in one country (Australia), where cannabis regulations and palliative care systems may differ from other jurisdictions. Action research methodology provides rich practical insights but isn't empirically generalizable. The considerations are drawn from experience with vaporized flower—trials using oils, edibles, or synthetic cannabinoids would face different challenges.
How to read the evidence
Action research methodology providing a practical framework—valuable for research design but not a source of clinical efficacy data.
When this study was published
Published in 2025 in the Journal of Pain and Symptom Management, reflecting current regulatory and practical challenges.
The bigger picture
This is the third paper from the same trial team: RTHC-00194 covered patient involvement in design, RTHC-00177 captured patient experiences with the product. Together, they form a comprehensive case study of how to conduct cannabis research in palliative care—from design philosophy (consumer contribution) through practical challenges (this paper) through patient experience (qualitative findings). For a field where many trials never get off the ground, this kind of methodological transparency is valuable.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Could standardized regulatory pathways for cannabis research reduce the burden described here? Would synthetic cannabinoids avoid some product variability issues while maintaining efficacy? How do different countries' cannabis regulations compare in terms of research feasibility?
Read the original research
Design Considerations for Medicinal Cannabis Clinical Trials in People Receiving Palliative Care.
Journal of pain and symptom management, 69(5), e395-e408
The Journal of Pain and Symptom Management is a reputable journal focusing on pain management and symptom control in clinical practice.
Citation
Razmovski-Naumovski, Valentina; Martin, Jennifer H; Chye, Richard; Phillips, Jane L; Lintzeris, Nicholas; Solowij, Nadia; Lee, Jessica; Lovell, Melanie; Noble, Bev; Galettis, Peter; Brown, Linda; Fazekas, Belinda; Clark, Katherine; Luckett, Tim; McCaffrey, Nikki; Currow, David C; Agar, Meera R. (2025). Design Considerations for Medicinal Cannabis Clinical Trials in People Receiving Palliative Care.. Journal of pain and symptom management, 69(5), e395-e408. https://doi.org/10.1016/j.jpainsymman.2025.02.009
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk